Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Leo Innovation Lab

- PMLiVE

Matt Ferriday announced as General Manager for LEO Pharma UK

Ferriday most recently held senior leadership roles at Ipsen Biopharma

- PMLiVE

LEO Pharma’s Anzupgo cream progresses to phase 3 trial for lichen sclerosus

There are currently no approved treatments specifically indicated for LS in the US or Europe

- PMLiVE

LEO Pharma receives NICE approval for chronic hand eczema cream

The cream can now be prescribed for patients when topical corticosteroids have not worked or are not suitable

- PMLiVE

LEO’s Anzupgo granted FDA approval to treat moderate-to-severe chronic hand eczema

The cream is now the first treatment approved by the regulator specifically for this patient population

- PMLiVE

LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

- PMLiVE

LEO Pharma and the Parker Institute join forces to advance dermatology research

The alliance will aim to discover molecules that could be incorporated into wider pharmaceutical research

- PMLiVE

LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

Approximately 125 million people worldwide are affected by some form of the inflammatory condition

- PMLiVE

LEO and DEBRA Research partner to advance epidermolysis bullosa treatments

There is currently no cure for the group of rare inherited skin disorders

- PMLiVE

LEO pharma gains EU rights to Junshi Biosciences’ PD-1 inhibitor toripalimab

The drug was approved by the EC last year to treat nasopharyngeal and oesophageal cancer

- PMLiVE

Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

- PMLiVE

LEO Pharma’s Anzupgo cream granted MHRA approval to treat chronic hand eczema

Anzupgo is the first topical pan-JAK inhibitor approved specifically for adults with moderate-to-severe cases

- PMLiVE

LEO Pharma shares final long-term results for atopic dermatitis drug Adbry

The inflammatory skin condition affects over 26 million people in the US alone

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links